B+
Bull case
25%
Probability
Target price
$11.40
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
HLN
HaleonBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Haleon's official H1 results showed improving operating quality: organic revenue grew 2.6%, Q2 accelerated to 3.1%, North America improved to 3.1%, Oral Health grew 6.2%, and adjusted operating profit rose 8.2% at constant currency. Productivity, free cash flow of £769m and continued brand investment could sustain EPS growth if volume/mix improves.
Posture
Constructive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Debt refinancing and interest costs remain monitoring items despite net leverage being in line with management's approximately 2.5-times objective.
Momentum
87
Value
64
Sentiment
47
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $9.50 · Bull $11.40 · Bear $7.80Analysis 2026-09-20; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $11.14
Why
Momentum87 · Δ7d +16.0
Value64 · Δ7d -0.1
Sentiment47 · Δ7d -1.1
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Debt refinancing and interest costs remain monitoring items despite net leverage being in line with management's approximately 2.5-times objective.
- • Margin expansion could slow as productivity benefits are reinvested or restructuring costs continue.
- • Revenue growth remains below Haleon's 4%-6% medium-term ambition, management described the consumer environment as challenging, and FY2026 guidance was unchanged at 3%-5% organic growth.
Catalyst clock
2026-08-21
Debt tender addresses the 2027 maturity
Lead driver: Value · See fundamentals
Momentum
87
8% active weight
Current posture
7d trendSoftening
Δ7d
+16.0
Δ21d
+48.8
Value
64
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.6
Sentiment
47
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-24.9
Why this grade
Composite grade B. Momentum 87.3 / Value 63.8 / Sentiment 47.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-20. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.80
Analysis reference price unavailable
Analysis 2026-09-20 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$44.66B
Beta
0.39
Shares Out
4.4B
P/E (TTM) · Derived
20.8
P/S (TTM)
-
P/FCF (TTM)
23.47
Rev YoY
-0.3%
EPS YoY
+7965.6%
Gross Margin
+65.5%
Op Margin
+23.3%
Net Debt
$9.8B
Current Ratio
0.69
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data